Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Decoy Therapeutics Inc.SLRX · Entity 937 | Chief Business Officer | February 18, 2020 | February 18, 2020 |
| Zomedica Corp.ZOM · Entity 6884 | Chief Financial Officer | March 17, 2025 | March 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Decoy Therapeutics Inc.
Report date February 18, 2020 · Filed February 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,609 |
Reported balance
After 2020-02-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-18 · Purchase · Acquired 11,300 · Balance 31,609 F1: Includes 2,538 shares of unvested Common Stock which will become fully vested on June 30, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,538 shares of unvested Common Stock which will become fully vested on June 30, 2020.
Zomedica Corp.
Report date March 17, 2025 · Filed March 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, without par valueSEC Table I · non-derivative | Direct | 300,000 |
Reported balance
After 2025-03-17 transaction · row 1
1 source rowRow 1 · 2025-03-17 · Purchase · Acquired 300,000 · Balance 300,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 19, 2025 15:47 UTC | Zomedica Corp. ZOM · Entity 6884 | PurchaseCommon Stock, without par value | 300,000 | $0.06 | $18,600.00 |
DisclosureSEC source: 0001654954-25-003016 · section16.xml · nonDerivative · entry 1 Jordan Scott · CIK 0001769747 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 19:16 UTC | Zomedica Corp. ZOM · Entity 6884 | GrantOptions to buy common stock · Derivative | 5,000,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001654954-25-000095 · section16.xml · derivative · entry 1 Jordan Scott · CIK 0001769747 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2034-12-31 F1 · derivative.exercise_date: The options shall vest over a period of four years; 25% shall vest on the first anniversary of the date of issuance and 1/48th shall vest each month thereafter Read SEC document |
| February 18, 2020 Filed Feb 18, 2020 21:48 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 11,300 | $0.90 | $10,170.00 |
DisclosureSEC source: 0001615219-20-000003 · wf-form4_158206246390469.xml · nonDerivative · entry 1 Jordan Scott · CIK 0001769747 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,609 F1 · balance_after: Includes 2,538 shares of unvested Common Stock which will become fully vested on June 30, 2020. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 01:59 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001615219-19-000035 · wf-form4_156833996436654.xml · derivative · entry 1 Jordan Scott · CIK 0001769747 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-10 F1 · derivative.exercise_date: The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 22:31 UTC Amendment | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001615219-19-000041 · wf-form4a_156841388132729.xml · derivative · entry 1 Jordan Scott · CIK 0001769747 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-10 F1 · derivative.exercise_date: The grant has a 4-year vesting schedule with 25% vesting on September 30, 2020 and 1/12th of the balance vesting on the last day of each calendar quarter thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.